PURPOSE: To retrospectively evaluate the efficacy and @entity137 of adjuvant radio-chemotherapy in @entity1 with @entity356 and to relate them to the outcome of the landmark INT0116 study that is criticized because of the high @entity137 and poor treatment compliance. METHODS: A total of 102 @entity1 who underwent postoperative @entity1487 ( @entity1487 )-based radio-chemotherapy in our institution between 2004 and 2010 for stage IB-IV (AJCC 6th Edn.) @entity356 were selected. Radiotherapy to 45 Gy was defined individually and delivered with 3D conformal technique. Chemotherapy was carried out during the first 4 and the last 3 days of radiotherapy with continuous infusion of @entity1487 (400mg/m  /day) and @entity4181 . @entity1 received an additional 3 cycles of chemotherapy of @entity1487 (425mg/m  /day), mostly 1 before and 2 after radio-chemotherapy. Acute @entity1503 were evaluated according to the CTC v3.0 scale. RESULTS: Stage distribution was as follows: IB-5 (5%), II-32 (31%), III-49 (48%), and IV-14 (14%). There were 96% R0 resections; 15% of the @entity1 had a D2 resection. Seventy-four @entity1 (72.5%) received all 5 planned cycles and 98 (96%) completed radiotherapy. The 3- and 5-year overall survival (OS) rates were 57% and 48%, respectively. Multivariate analysis showed that variables significantly affecting OS were pT3-T4, pN2-3, R1 resection and female gender. Only 2% of the @entity1 experienced grade 3 gastrointestinal @entity137 ; 7% had grade 3 or higher hematological @entity137 . CONCLUSIONS: We demonstrated better treatment tolerance, compliance, OS of adjuvant radio-chemotherapy for @entity356 in comparison with INT0116 study. Conformal radiation techniques might have contributed to this improvement.

Clinical outcome and XXXX of 3D-conformal radiotherapy combined with chemotherapy based on the Intergroup SWOG 9008/INT0116 study protocol for @entity356 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological and gastrointestinal toxicities'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', 'fluorouracil']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
